Physician profile
Edwin R Bonilla
NPI 1891806121
$366.38
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.60 · 2023: $107 · 2024: $120 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.78 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $43.30 | 2023-2024 | Austedo Xr |
| Amgen INC. | $33.93 | 2023-2024 | Repatha, Otezla |
| Bausch Health US, LLC | $30.31 | 2025 | Wellbutrin |
| Abbott Laboratories | $30.28 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.41 | 2023-2024 | Jardiance |
| Lundbeck LLC | $21.11 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $19.18 | 2023 | |
| Lilly USA, LLC | $15.08 | 2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $14.02 | 2024 | Veozah |
| Intuitive Surgical, INC. | $11.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Bonilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.